Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses CVS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CVS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| J. David Joyner | $1,500,000 | $0 | $14,499,931 | $0 | $4,695,900 | $64,644 | $453,609 | $21,214,084 |
| President and Chief Executive Officer | ||||||||
| Prem Shah | 1,100,000 | 0 | 7,199,920 | 1,799,993 | 3,013,000 | 0 | 266,297 | 13,379,210 |
| Executive Vice President and Group President | ||||||||
| Steven Nelson | 1,000,000 | 0 | 5,799,915 | 1,449,994 | 2,988,000 | 0 | 349,201 | 11,587,110 |
| Executive Vice President and President, Aetna | ||||||||
| Tilak Mandadi | 1,000,000 | 0 | 5,599,965 | 1,399,996 | 2,561,000 | 0 | 416,755 | 10,977,716 |
| Executive Vice President, Ventures and Chief Experience and Technology Officer | ||||||||
| Brian Newman | 696,970 | 0 | 5,599,950 | 1,399,989 | 1,562,000 | 0 | 161,599 | 9,420,508 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Thomas Cowhey | 420,833 | 0 | 4,399,978 | 1,099,995 | 0 | 3,097 | 791,235 | 6,715,138 |
| Former Executive Vice President and Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| J. David Joyner | $21,214,084 | $17,808,792 | — | +3,405,292 |
| Prem Shah | 13,379,210 | — | 8,582,366 | — |
| Steven Nelson | 11,587,110 | — | — | — |
| Tilak Mandadi | 10,977,716 | 11,361,343 | 8,881,845 | −383,627 |
| Brian Newman | 9,420,508 | — | — | — |
| Thomas Cowhey | 6,715,138 | — | 4,579,937 | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Tilak Mandadi | EVP, Chief Exp & Tech Officer | 2026-05-08 | D | 69,551 | $90 | $6,230,379 | Common | Form 4 ↗ |
| Alecia A. DeCoudreaux | Director | 2026-05-14 | A | 1,447.5 | 97 | 140,625 | Derivative, Class A Common | Form 4 ↗ |
| Guy P. Sansone | Director | 2026-05-14 | A | 1,447 | 97 | 140,576 | Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-05-14 | A | 1,447 | 97 | 140,576 | Common | Form 4 ↗ |
| Michael F. Mahoney | Director | 2026-05-14 | A | 1,737 | 97 | 168,750 | Derivative, Class A Common | Form 4 ↗ |
| John E. Gallina | Director | 2026-05-14 | A | 1,447.5 | 97 | 140,625 | Derivative, Class A Common | Form 4 ↗ |
| Fernando Aguirre | Director | 2026-05-14 | A | 1,563 | 97 | 151,845 | Common | Form 4 ↗ |
| Anne M. Finucane | Director | 2026-05-14 | A | 1,544 | 97 | 150,000 | Derivative, Class A Common | Form 4 ↗ |
| Larry M. Robbins | Director | 2026-05-14 | A | 1,930.01 | 97 | 187,500 | Derivative, Class A Common | Form 4 ↗ |
| Douglas H. Shulman | Director | 2026-05-14 | A | 1,447.5 | 97 | 140,625 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey R. Balser | Director | 2026-05-14 | A | 2,058 | 97 | 199,935 | Common | Form 4 ↗ |
| C. David Brown II | Director | 2026-05-14 | A | 1,544 | 97 | 150,000 | Common | Form 4 ↗ |
| J. Scott Kirby | Director | 2026-05-14 | A | 1,447 | 97 | 140,576 | Common | Form 4 ↗ |
| Larry M. Robbins | Director | 2026-05-19 | D | 152,691 | 95 | 14,476,038 | Common, indirect | Form 4 ↗ |
| Larry M. Robbins | Director | 2026-05-19 | D | 151 | 95 | 14,372 | Common, indirect | Form 4 ↗ |
| Larry M. Robbins | Director | 2026-05-19 | D | 66,881 | 96 | 6,398,204 | Common, indirect | Form 4 ↗ |
| Larry M. Robbins | Director | 2026-05-19 | D | 370,462 | 93 | 34,619,007 | Common, indirect | Form 4 ↗ |
| Larry M. Robbins | Director | 2026-05-19 | D | 800 | 96 | 77,026 | Common, indirect | Form 4 ↗ |
| Larry M. Robbins | Director | 2026-05-19 | D | 378,000 | 93 | 35,271,558 | Derivative, Class A Common | Form 4 ↗ |
| Larry M. Robbins | Director | 2026-05-19 | D | 1,983,387 | 94 | 187,326,935 | Common, indirect | Form 4 ↗ |
| Larry M. Robbins | Director | 2026-05-19 | D | 797,628 | 93 | 74,559,554 | Common, indirect | Form 4 ↗ |
| Fernando Aguirre | Director | 2026-05-20 | D | 1,563 | 94 | 146,142 | Common | Form 4 ↗ |
| Fernando Aguirre | Director | 2026-05-20 | D | 30,437 | 94 | 2,854,230 | Common | Form 4 ↗ |
| Brian Newman | EVP, Chief Financial Officer | 2026-05-31 | D | 2,478 | 91 | 225,448 | Common | Form 4 ↗ |
| Amy Compton-Phillips | EVP, Chief Medical Officer | 2026-05-31 | D | 7,618 | 91 | 693,086 | Common | Form 4 ↗ |
| James David Clark | SVP, Cont & Chief Acct Officer | 2026-06-26 | D | 454 | 91 | 41,305 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| J. David Joyner | RSU | 2025-02-06 | — | — | 53,324 | — | $3,624,966 |
| Steven Nelson | Equity | 2025-02-06 | — | — | 21,329 | — | 1,449,945 |
| Thomas Cowhey | Equity | 2025-02-06 | — | — | 16,181 | — | 1,099,984 |
| Prem Shah | PSU | 2025-02-06 | — | — | — | — | 5,399,946 |
| Brian Newman | OPTION | 2025-04-01 | — | — | 94,786 | — | 1,399,989 |
| Tilak Mandadi | OPTION | 2025-02-06 | — | — | 87,336 | — | 1,399,996 |
| Thomas Cowhey | OPTION | 2025-02-06 | — | — | 68,621 | — | 1,099,995 |
| J. David Joyner | Equity | 2025-02-06 | — | — | — | — | 10,874,965 |
| Brian Newman | PSU | 2025-04-01 | — | — | — | — | 4,199,972 |
| Tilak Mandadi | PSU | 2025-02-06 | — | — | — | — | 4,199,985 |
| Prem Shah | Equity | 2025-02-06 | — | — | 26,478 | — | 1,799,974 |
| Brian Newman | Equity | 2025-04-01 | — | — | 21,861 | — | 1,399,978 |
| Steven Nelson | OPTION | 2025-02-06 | — | — | 90,455 | — | 1,449,994 |
| Thomas Cowhey | PSU | 2025-02-06 | — | — | — | — | 3,299,994 |
| Steven Nelson | PSU | 2025-02-06 | — | — | — | — | 4,349,970 |
| Prem Shah | OPTION | 2025-02-06 | — | — | 112,289 | — | 1,799,993 |
| Tilak Mandadi | Equity | 2025-02-06 | — | — | 20,594 | — | 1,399,980 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| J. David Joyner | $3,624,966 | $0 | $0 | 0.0% |
| Steven Nelson | 0 | 4,349,970 | 1,449,994 | 75.0% |
| Thomas Cowhey | 0 | 3,299,994 | 1,099,995 | 75.0% |
| Prem Shah | 0 | 5,399,946 | 1,799,993 | 75.0% |
| Brian Newman | 0 | 4,199,972 | 1,399,989 | 75.0% |
| Tilak Mandadi | 0 | 4,199,985 | 1,399,996 | 75.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| J. David Joyner | RSU | 7,981 | — | $633,372 |
| Tilak Mandadi | RSU | 30,732 | — | 2,438,892 |
| Thomas Cowhey | PSU | 6,908 | — | 548,219 |
| Thomas Cowhey | RSU | 3,896 | — | 309,187 |
| Thomas Cowhey | RSU | 2,396 | — | 190,147 |
| J. David Joyner | PSU | 29,361 | — | 2,330,089 |
| Steven Nelson | PSU | 54,641 | — | 4,336,310 |
| Prem Shah | PSU | 46,978 | — | 3,728,174 |
| Brian Newman | PSU | 56,217 | — | 4,461,381 |
| J. David Joyner | RSU | 53,324 | — | 4,231,793 |
| Tilak Mandadi | PSU | 50,893 | — | 4,038,868 |
| Prem Shah | RSU | 28,368 | — | 2,251,284 |
| J. David Joyner | Option | 25,980 | 74.31 | — |
| Steven Nelson | Option | 90,455 | 67.98 | — |
| Tilak Mandadi | Option | 87,336 | 67.98 | — |
| Prem Shah | RSU | 26,478 | — | 2,101,294 |
| Prem Shah | Option | 44,537 | 74.31 | — |
| Tilak Mandadi | Option | 50,940 | 79.56 | — |
| Tilak Mandadi | Option | 48,248 | 74.31 | — |
| Thomas Cowhey | Option | 5,198 | 101.09 | — |
| Prem Shah | Option | 10,395 | 101.09 | — |
| Prem Shah | Option | 497,515 | 71.82 | — |
| Brian Newman | Option | 94,786 | 64.04 | — |
| J. David Joyner | RSU | 21,210 | — | 1,683,226 |
| J. David Joyner | Option | 995,030 | 71.82 | — |
| J. David Joyner | PSU | 136,603 | — | 10,840,814 |
| Prem Shah | PSU | 67,830 | — | 5,382,989 |
| Prem Shah | Option | 112,289 | 67.98 | — |
| Tilak Mandadi | PSU | 52,757 | — | 4,186,796 |
| Steven Nelson | Option | 82,920 | 71.82 | — |
| Tilak Mandadi | RSU | 33,417 | — | 2,651,973 |
| Thomas Cowhey | PSU | 23,489 | — | 1,864,087 |
| Brian Newman | RSU | 21,861 | — | 1,734,889 |
| Steven Nelson | RSU | 21,329 | — | 1,692,669 |
| Tilak Mandadi | RSU | 20,594 | — | 1,634,340 |
| J. David Joyner | RSU | 16,548 | — | 1,313,249 |
| Prem Shah | Option | 47,022 | 79.56 | — |
| Tilak Mandadi | RSU | 12,255 | — | 972,557 |
| Prem Shah | RSU | 11,312 | — | 897,720 |
| Thomas Cowhey | Option | 17,155 | 67.98 | — |
| Thomas Cowhey | RSU | 7,739 | — | 614,167 |
| Thomas Cowhey | RSU | 7,108 | — | 564,091 |
| Thomas Cowhey | Option | 15,674 | 79.56 | — |
| Thomas Cowhey | RSU | 3,640 | — | 288,870 |
| Thomas Cowhey | Option | 8,351 | 74.31 | — |
Although we consider numerous factors in our pay decisions, these five core principles drive our executive compensation philosophy
| CEO STI target (% of salary) | 200% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Korn Ferry |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-14 | 976,252,194 | 59,088,923 | 3,377,357 | 93.99% | Passed |
| 2025 | 2025-05-15 | 597,945,237 | 413,324,138 | 2,753,876 | 59.13% | Passed |
| 2024 | 2024-05-16 | 818,001,447 | 139,313,232 | 3,692,720 | 85.45% | Passed |
| 2023 | 2023-05-18 | 745,115,461 | 185,740,147 | 4,744,214 | 80.05% | Passed |
| 2022 | 2022-05-11 | 903,024,507 | 80,791,141 | 3,635,231 | 91.79% | Passed |
| 2021 | 2021-05-13 | 851,824,270 | 91,423,549 | 3,741,911 | 90.31% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-14 | 93.99%a |
| 2025 | 2025-05-15 | 59.13%b |
| 2024 | 2024-05-16 | 85.45%c |
a. Approved under the standard stated in the filing — “Abstentions are counted as shares present or represented and voting and have the effect of a vote against.”.
b. Approved under the standard stated in the filing — “Votes "against" a director's election will count as votes cast, but "abstentions" and "broker non-votes" will not count as votes cast with respect to that director's election and will have no effect on the vote.”.
c. Approved under the standard stated in the filing — “Votes "against" a director's election will count as votes cast, but "abstentions" and "broker non-votes" will not count as votes cast with respect to that director's election and will have no effect.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 336 : 1 |
|---|---|
| CEO total compensation | $21,214,084 |
| Median employee compensation | $63,262 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Michael F. MahoneyIndependent · Lead Independent Director · Nominating and Corporate Governance (Chair) · Management Planning and Development · Executive | $105,459 | $316,208 | $0 | — | $0 | $421,667 |
| Fernando AguirreIndependent · Audit (Chair) · Management Planning and Development | 91,284 | 273,716 | 0 | — | 0 | 365,000 |
| Jeffrey R. BalserIndependent · Audit · Health Services and Technology (Chair) · Executive | 90,060 | 269,940 | 0 | — | 0 | 360,000 |
| C. David Brown IIIndependent · Management Planning and Development (Chair) · Nominating and Corporate Governance | 90,060 | 269,940 | 0 | — | 0 | 360,000 |
| Anne M. FinucaneIndependent · Audit · Management Planning and Development · Public Policy and External Affairs (Chair) | 90 | 260,625 | 0 | — | 86,785 | 347,500 |
| Leslie V. NorwalkNot independent · Health Services and Technology | 83,786 | 251,214 | 0 | — | 0 | 335,000 |
| Larry M. RobbinsIndependent · Audit | 0 | 251,250 | 0 | — | 83,750 | 335,000 |
| Alecia A. DeCoudreauxIndependent · Health Services and Technology · Nominating and Corporate Governance | 83,750 | 251,250 | 0 | — | 0 | 335,000 |
| Douglas H. ShulmanIndependent · Management Planning and Development · Health Services and Technology | 83,786 | 251,214 | 0 | — | 0 | 335,000 |
| J. Scott KirbyIndependent · Health Services and Technology · Nominating and Corporate Governance | 41,940 | 251,185 | 0 | — | 41,875 | 335,000 |
| Guy P. SansoneIndependent · Audit | 83,786 | 251,214 | 0 | — | 0 | 335,000 |
| Nancy-Ann M. DeParleIndependent · Not standing for re-election · Departed during FY | 0 | 0 | 0 | 0 | 0 | 0 |
| Roger N. FarahNot independent · Executive (Chair) | 0 | 0 | 0 | — | 0 | 0 |
| J. David JoynerEmployee director · Board Chair · Executive | 0 | 0 | 0 | — | 0 | 0 |
| Jean-Pierre MillonIndependent · Not standing for re-election · Departed during FY | 0 | 0 | 0 | 0 | 0 | 0 |
| Mary L. SchapiroIndependent · Not standing for re-election · Departed during FY | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $83,750 |
|---|---|
| Annual equity retainer | $251,250 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 25,000 / 25,000 |
| Stock ownership guideline | $10,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $754,001 |
| Equity awards (grant-date value) | $2,897,756 |
| All other compensation | $212,410 |
| Total cost of the board | $3,864,167 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies CVS Health names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including CVS Health.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | UnitedHealth Group Incorporated | 2025 | Stephen Hemsley | $596,154 | $0 | $60,000,024 | $0 | $60,938,062 |
| 2 | Eli Lilly and Company | 2025 | David Ricks | 1,700,000 | 23,325,000 | 0 | 6,485,500 | 36,698,337 |
| 3 | AbbVie Inc. | 2025 | Robert Michael | 1,700,000 | 13,268,456 | 3,199,154 | 5,200,000 | 32,530,984 |
| 4 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 5 | Baxter International Inc. | 2025 | Andrew Hider | 499,315 | 23,133,518 | 3,185,053 | 820,125 | 29,805,182 |
| 6 | Walmart Inc. | 2026 | Doug McMillon | 1,500,000 | 21,051,605 | 0 | 4,032,000 | 29,240,930 |
| 7 | HCA Healthcare, Inc. | 2025 | Samuel Hazen | 1,577,815 | 8,474,543 | 8,514,090 | 5,416,732 | 26,456,606 |
| 8 | Danaher Corporation | 2025 | Rainer Blair | 1,400,000 | 9,292,370 | 8,386,657 | 4,194,400 | 23,795,280 |
| 9 | Boston Scientific Corporation | 2025 | Michael Mahoney | 1,442,603 | 13,608,056 | 3,749,980 | 4,002,001 | 23,532,050 |
| 10 | Medtronic plc | 2026 | Geoffrey Martha | 1,399,039 | 13,672,200 | 5,175,559 | 2,307,200 | 22,940,252 |
| 11 | The Cigna Group | 2025 | David Cordani | 1,600,000 | 13,929,161 | 3,400,019 | 3,200,000 | 22,866,134 |
| 12 | Elevance Health, Inc. | 2025 | Gail Boudreaux | 1,600,000 | 13,440,277 | 4,199,765 | 2,768,000 | 22,582,314 |
| 13 | Target Corporation | 2025 | Brian Cornell | 1,400,000 | 18,555,280 | 0 | 787,920 | 21,830,088 |
| 14 | Stryker Corporation | 2025 | Kevin Lobo | 1,500,000 | 16,684,917 | 0 | 2,250,000 | 21,401,495 |
| 15 | CVS Health | 2025 | J. David Joyner | 1,500,000 | 14,499,931 | 0 | 4,695,900 | 21,214,084 |
| 16 | Moderna, Inc. | 2025 | Stéphane Bancel | 1,677,739 | 6,897,455 | 6,897,425 | 4,302,360 | 19,932,217 |
| 17 | Centene Corporation | 2025 | Sarah London | 1,473,077 | 15,537,733 | 0 | 2,109,446 | 19,506,298 |
| 18 | Insulet Corp. | 2025 | Ashley McEvoy | 729,808 | 12,958,850 | 2,999,913 | 2,031,562 | 18,858,968 |
| 19 | Humana Inc. | 2025 | James Rechtin | 1,348,558 | 13,868,141 | 0 | 3,034,740 | 18,757,075 |
| 20 | DaVita Inc. | 2025 | Javier Rodriguez | 1,500,000 | 11,442,481 | 2,699,982 | 2,089,491 | 18,210,597 |
| 21 | Becton, Dickinson and Company | 2025 | Thomas Polen | 1,395,463 | 9,991,854 | 3,311,861 | 1,852,010 | 17,129,140 |
| 22 | Quest Diagnostics Incorporated | 2025 | James Davis | 1,250,000 | 8,762,861 | 2,999,873 | 2,205,844 | 15,498,479 |
| 23 | ResMed Inc. | 2025 | Michael Farrell | 1,214,150 | 8,775,059 | 2,925,007 | 1,646,743 | 14,674,543 |
| 24 | IDEXX Laboratories, Inc. | 2025 | Jonathan Mazelsky | 1,150,000 | 5,399,881 | 5,400,001 | 2,593,000 | 14,580,122 |
| 25 | Waters Corporation | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 26 | Revvity, Inc. | 2025 | Prahlad R. Singh | 1,129,231 | 7,694,985 | 2,559,152 | 2,385,450 | 13,809,549 |
| 27 | Henry Schein, Inc. | 2025 | Stanley Bergman | 1,707,000 | 7,764,800 | 0 | 2,289,251 | 12,013,915 |
| 28 | Bio-Techne Corporation | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 29 | DexCom, Inc. | 2025 | Jacob Leach | 768,962 | 5,936,062 | 0 | 1,164,780 | 7,985,960 |
| 30 | Teleflex Incorporated | 2025 | Liam Kelly | 1,144,400 | 2,005,604 | 2,886,518 | 227,280 | 6,732,419 |
| 31 | Walgreens Boots Alliance, Inc. | 2024 | Ginger Graham | 0 | 0 | 0 | 0 | 2,500,000 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| CVS Health | 156.5% | PSU 60 · RSU 20 · Options 20 | Yes — rTSR Modifier | Korn Ferry |
| AbbVie Inc. | not disclosed | PSU 40 · RSU 40 · Options 20 | Yes — Relative TSR | Semler Brossy |
| Baxter International Inc. | not disclosed | PSU 50 · Stock Options 25 · RSU 25 | not disclosed | Aon |
| Becton, Dickinson and Company | 85% | PSU 50 · Options 25 · RSU 25 | No | Semler Brossy |
| Bio-Techne Corporation | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon Talent |
| Boston Scientific Corporation | 173% | PSU 50 · RSU 25 · Options 25 | No | Semler Brossy Consulting Group, LLC |
| Centene Corporation | 71.6% | PSU 60 · RSU 40 | Yes — Relative TSR | FW Cook |
| Danaher Corporation | not disclosed | Options 50 · RSU 50 | not disclosed | FW Cook |
| DaVita Inc. | 93% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR v. S&P Health Care Services Select Industry Index | Compensia |
| DexCom, Inc. | not disclosed | not disclosed | Yes — Relative TSR Performance Metric | Aon Hewitt Consulting Company |
| Elevance Health, Inc. | 86.5% | PSU 52 · RSU 24 · Options 24 | No | Willis Towers Watson (WTW) |
| Eli Lilly and Company | 218% | PSU 100 | No | FW Cook |
| HCA Healthcare, Inc. | 195.78% | SAR 50 · PSU 50 | No | Semler Brossy |
| Henry Schein, Inc. | 89.3% | PSU 65 · RSU 35 | No | Pearl Meyer |
| Humana Inc. | 112% | PSU 60 · RSU 40 | Yes — Relative TSR | Farient Advisors, LLC |
| IDEXX Laboratories, Inc. | 140% | Options 50 · PSU 50 | No | Farient |
| Incyte Corporation | 138.6% | PSU 60 · Options 20 · RSU 20 | Yes — relative total shareholder return (TSR) | Aon |
| Insulet Corp. | 195.8% | PSU 60 · RSU 20 · Options 20 | No | Pearl Meyer & Partners, LLC |
| Medtronic plc | 103% | PSU 50 · Options 30 · RSU 20 | No | Semler Brossy |
| Moderna, Inc. | 170% | PSU 50 · Options 50 | No | Pay Governance LLC |
| Quest Diagnostics Incorporated | not disclosed | not disclosed | not disclosed | Semler Brossy |
| ResMed Inc. | 102% | PSU 50 · RSU 25 · Options 25 | Yes — Absolute TSR | FW Cook, Inc. |
| Revvity, Inc. | 124% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Stryker Corporation | 100% | PSU 48 · Options 34 | No | Semler Brossy |
| Target Corporation | not disclosed | PSU 60 · RSU 40 | No | Semler Brossy |
| Teleflex Incorporated | 25.9% | Options 55 · RSU 25 · PSU 20 | Yes — Absolute TSR | FW Cook |
| The Cigna Group | 100% | PSU 60 · RSU 20 · Options 20 | No | Pay Governance |
| UnitedHealth Group Incorporated | not disclosed | PSU 50 · Options 25 · RSU 25 | No | Pay Governance |
| Walgreens Boots Alliance, Inc. | not disclosed | RSU 100 | not disclosed | Mercer |
| Walmart Inc. | 112% | not disclosed | No | Farient Advisors LLC |
| Waters Corporation | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, J. David Joyner | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Summary Compensation Table” · page 77. As printed: 21,214,084. Filing ↗machine: r1 · c18 · span 969864–969874 |
| 2 | Section 01, Prem Shah | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Summary Compensation Table” · page 77. As printed: 13,379,210. Filing ↗machine: r9 · c18 · span 982220–982230 |
| 3 | Section 01, Steven Nelson | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Summary Compensation Table” · page 77. As printed: 11,587,110. Filing ↗machine: r7 · c18 · span 979040–979050 |
| 4 | Section 01, Tilak Mandadi | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Summary Compensation Table” · page 77. As printed: 10,977,716. Filing ↗machine: r4 · c18 · span 974982–974992 |
| 5 | Section 01, Brian Newman | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Summary Compensation Table” · page 77. As printed: 9,420,508. Filing ↗machine: r3 · c18 · span 973105–973114 |
| 6 | Section 01, Thomas Cowhey | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Summary Compensation Table” · page 77. As printed: 6,715,138. Filing ↗machine: r12 · c18 · span 987046–987055 |
| 7 | Section 03, J. David Joyner RSU | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t315 · r4 · c20 · span 1036232–1036238 |
| 8 | Section 03, Steven Nelson Equity | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t252 · r4 · c7 · span 834139–834148 |
| 9 | Section 03, Thomas Cowhey Equity | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t252 · r6 · c7 · span 836311–836320 |
| 10 | Section 03, Prem Shah PSU | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t252 · r5 · c3 · span 834948–834957 |
| 11 | Section 03, Brian Newman OPTION | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t315 · r6 · c22 · span 1042425–1042431 |
| 12 | Section 03, Tilak Mandadi OPTION | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards – 2025” · grants of plan-based awards table. Filing ↗machine: t252 · r3 · c11 · span 833326–833335 |
| 13 | Section 03, Thomas Cowhey OPTION | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards – 2025” · grants of plan-based awards table. Filing ↗machine: t252 · r6 · c11 · span 836585–836594 |
| 14 | Section 03, J. David Joyner Equity | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t252 · r1 · c3 · span 830314–830324 |
| 15 | Section 03, Brian Newman PSU | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t252 · r2 · c3 · span 831562–831571 |
| 16 | Section 03, Tilak Mandadi PSU | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t252 · r3 · c3 · span 832690–832699 |
| 17 | Section 03, Prem Shah Equity | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t252 · r5 · c7 · span 835266–835275 |
| 18 | Section 03, Brian Newman Equity | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t252 · r2 · c7 · span 831880–831889 |
| 19 | Section 03, Steven Nelson OPTION | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards – 2025” · grants of plan-based awards table. Filing ↗machine: t252 · r4 · c11 · span 834457–834466 |
| 20 | Section 03, Thomas Cowhey PSU | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t252 · r6 · c3 · span 836037–836046 |
| 21 | Section 03, Steven Nelson PSU | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t252 · r4 · c3 · span 833821–833830 |
| 22 | Section 03, Prem Shah OPTION | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards – 2025” · grants of plan-based awards table. Filing ↗machine: t252 · r5 · c11 · span 835584–835593 |
| 23 | Section 03, Tilak Mandadi Equity | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t315 · r12 · c20 · span 1059726–1059732 |
| 24 | Section 07, pay ratio | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “CEO Pay Ratio”. As printed: 336 : 1. Filing ↗machine: span 1326591–1326599 |
| 25 | Section 08, Michael F. Mahoney | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 421,667. Filing ↗machine: t143 · r7 · c10 · span 555395–555402 |
| 26 | Section 08, Fernando Aguirre | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 365,000. Filing ↗machine: t143 · r1 · c10 · span 547667–547674 |
| 27 | Section 08, Jeffrey R. Balser | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 360,000. Filing ↗machine: t143 · r2 · c10 · span 548961–548968 |
| 28 | Section 08, C. David Brown II | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 360,000. Filing ↗machine: t143 · r3 · c10 · span 550243–550250 |
| 29 | Section 08, Anne M. Finucane | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 347,500. Filing ↗machine: t143 · r5 · c10 · span 552819–552826 |
| 30 | Section 08, Leslie V. Norwalk | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 335,000. Filing ↗machine: t143 · r8 · c10 · span 556677–556684 |
| 31 | Section 08, Larry M. Robbins | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 335,000. Filing ↗machine: t143 · r9 · c10 · span 557958–557965 |
| 32 | Section 08, Alecia A. DeCoudreaux | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 335,000. Filing ↗machine: t143 · r4 · c10 · span 551529–551536 |
| 33 | Section 08, Douglas H. Shulman | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 335,000. Filing ↗machine: t143 · r11 · c10 · span 560399–560406 |
| 34 | Section 08, J. Scott Kirby | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 335,000. Filing ↗machine: t143 · r6 · c10 · span 554097–554104 |
| 35 | Section 08, Guy P. Sansone | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 335,000. Filing ↗machine: t143 · r10 · c10 · span 559237–559244 |
| 36 | Section 08, Nancy-Ann M. DeParle | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 37 | Section 08, Roger N. Farah | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 38 | Section 08, J. David Joyner | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 39 | Section 08, Jean-Pierre Millon | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 40 | Section 08, Mary L. Schapiro | DEF 14A | 2026-04-03 | 0001308179-26-000201 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 41 | Section 02, Tilak Mandadi 2026-05-08 | Form 4 | 2026-05-11 | 0000064803-26-000056 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Alecia A. DeCoudreaux 2026-05-14 | Form 4 | 2026-05-15 | 0000064803-26-000066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Guy P. Sansone 2026-05-14 | Form 4 | 2026-05-15 | 0000064803-26-000068 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Leslie V. Norwalk 2026-05-14 | Form 4 | 2026-05-15 | 0000064803-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Michael F. Mahoney 2026-05-14 | Form 4 | 2026-05-15 | 0000064803-26-000078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, John E. Gallina 2026-05-14 | Form 4 | 2026-05-15 | 0000064803-26-000080 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Fernando Aguirre 2026-05-14 | Form 4 | 2026-05-15 | 0000064803-26-000076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Anne M. Finucane 2026-05-14 | Form 4 | 2026-05-15 | 0000064803-26-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Larry M. Robbins 2026-05-14 | Form 4 | 2026-05-15 | 0000064803-26-000058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Douglas H. Shulman 2026-05-14 | Form 4 | 2026-05-15 | 0000064803-26-000060 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Jeffrey R. Balser 2026-05-14 | Form 4 | 2026-05-15 | 0000064803-26-000074 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, C. David Brown II 2026-05-14 | Form 4 | 2026-05-15 | 0000064803-26-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, J. Scott Kirby 2026-05-14 | Form 4 | 2026-05-15 | 0000064803-26-000072 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Larry M. Robbins 2026-05-19 | Form 4 | 2026-05-21 | 0000905148-26-002617 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Larry M. Robbins 2026-05-19 | Form 4 | 2026-05-21 | 0000905148-26-002617 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Larry M. Robbins 2026-05-19 | Form 4 | 2026-05-21 | 0000905148-26-002617 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Larry M. Robbins 2026-05-19 | Form 4 | 2026-05-21 | 0000905148-26-002617 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Larry M. Robbins 2026-05-19 | Form 4 | 2026-05-21 | 0000905148-26-002617 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Larry M. Robbins 2026-05-19 | Form 4 | 2026-05-21 | 0000905148-26-002617 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Larry M. Robbins 2026-05-19 | Form 4 | 2026-05-21 | 0000905148-26-002617 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Larry M. Robbins 2026-05-19 | Form 4 | 2026-05-21 | 0000905148-26-002617 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Fernando Aguirre 2026-05-20 | Form 4 | 2026-05-22 | 0000064803-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Fernando Aguirre 2026-05-20 | Form 4 | 2026-05-22 | 0000064803-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Brian Newman 2026-05-31 | Form 4 | 2026-06-01 | 0000064803-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Amy Compton-Phillips 2026-05-31 | Form 4 | 2026-06-01 | 0000064803-26-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, James David Clark 2026-06-26 | Form 4 | 2026-06-29 | 0000064803-26-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 06, 2026 vote | Form 8-K | 2026-05-18 | 0000064803-26-000082 | Item 5.07 · say-on-pay result. As reported: 93.99% (votes for as printed: 976,252,194). Filing ↗ |
| 68 | Section 06, 2025 vote | Form 8-K | 2025-05-20 | 0000064803-25-000015 | Item 5.07 · say-on-pay result. As reported: 59.13% (votes for as printed: 597,945,237). Filing ↗ |
| 69 | Section 06, 2024 vote | Form 8-K | 2024-05-22 | 0000064803-24-000019 | Item 5.07 · say-on-pay result. As reported: 85.45% (votes for as printed: 818,001,447). Filing ↗ |
| 70 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 71 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 72 | Section 09b board cost (computed) | Computed | — | computed | Cash 754,001 + equity 2,897,756 + all other 212,410 = 3,864,167, summed across the director compensation table rows.machine: formula: Σ = 3,864,167 |
| 73 | UnitedHealth Group Incorporated, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001104659-26-046125 | CEO total compensation as printed in UnitedHealth Group Incorporated's own proxy. As printed: 60,938,062. Filing ↗machine: r1 · c48 · span 1832651–1832661 |
| 74 | Eli Lilly and Company, Section 10b CEO total | DEF 14A | 2026-03-20 | 0000059478-26-000029 | CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. Filing ↗machine: t92 · r2 · c20 · span 925013–925024 |
| 75 | AbbVie Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001104659-26-033387 | CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. Filing ↗machine: t210 · r9 · c26 · span 1414083–1414093 |
| 76 | Incyte Corporation, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 77 | Baxter International Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001628280-26-020330 | CEO total compensation as printed in Baxter International Inc.'s own proxy. As printed: 29,805,182. Filing ↗machine: r4 · c30 · span 1451066–1451076 |
| 78 | Walmart Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173673 | CEO total compensation as printed in Walmart Inc.'s own proxy. As printed: 29,240,930. Filing ↗machine: r4 · c16 · span 3840466–3840476 |
| 79 | HCA Healthcare, Inc., Section 10b CEO total | DEF 14A | 2026-03-13 | 0001193125-26-106142 | CEO total compensation as printed in HCA Healthcare, Inc.'s own proxy. As printed: 26,456,606. Filing ↗machine: span 784078–784088 |
| 80 | Danaher Corporation, Section 10b CEO total | DEF 14A | 2026-03-25 | 0000313616-26-000101 | CEO total compensation as printed in Danaher Corporation's own proxy. As printed: 23,795,280. Filing ↗machine: t122 · r2 · c21 · span 1070180–1070190 |
| 81 | Boston Scientific Corporation, Section 10b CEO total | DEF 14A | 2026-03-18 | 0000885725-26-000025 | CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. Filing ↗machine: r2 · c27 · span 1249807–1249817 |
| 82 | Medtronic plc, Section 10b CEO total | DEF 14A | 2026-08-17 | 0001613103-26-000010 | CEO total compensation as printed in Medtronic plc's own proxy. As printed: 22,940,252. Filing ↗machine: span 988220–988230 |
| 83 | The Cigna Group, Section 10b CEO total | DEF 14A | 2026-03-13 | 0001739940-26-000023 | CEO total compensation as printed in The Cigna Group's own proxy. As printed: 22,866,134. Filing ↗machine: t303 · r3 · c16 · span 1360729–1360739 |
| 84 | Elevance Health, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001156039-26-000031 | CEO total compensation as printed in Elevance Health, Inc.'s own proxy. As printed: 22,582,314. Filing ↗machine: span 1161376–1161386 |
| 85 | Target Corporation, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001628280-26-027508 | CEO total compensation as printed in Target Corporation's own proxy. As printed: 21,830,088. Filing ↗machine: r2 · c8 · span 2775825–2775836 |
| 86 | Stryker Corporation, Section 10b CEO total | DEF 14A | 2026-03-23 | 0000310764-26-000013 | CEO total compensation as printed in Stryker Corporation's own proxy. As printed: 21,401,495. Filing ↗machine: t101 · r2 · c7 · span 1584979–1584989 |
| 87 | CVS Health (subject), Section 10b CEO total | DEF 14A | 2026-04-03 | 0001308179-26-000201 | CEO total compensation as printed in CVS Health's own proxy. As printed: 21,214,084. Filing ↗machine: r1 · c18 · span 969864–969874 |
| 88 | Moderna, Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001308179-26-000081 | CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898 |
| 89 | Centene Corporation, Section 10b CEO total | DEF 14A | 2026-03-26 | 0001071739-26-000077 | CEO total compensation as printed in Centene Corporation's own proxy. As printed: 19,506,298. Filing ↗machine: r2 · c30 · span 1494721–1494732 |
| 90 | Insulet Corp., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013333 | CEO total compensation as printed in Insulet Corp.'s own proxy. As printed: 18,858,968. Filing ↗machine: t218 · r3 · c25 · span 1028076–1028087 |
| 91 | Humana Inc., Section 10b CEO total | DEF 14A | 2026-03-06 | 0001104659-26-024799 | CEO total compensation as printed in Humana Inc.'s own proxy. As printed: 18,757,075. Filing ↗machine: t157 · r1 · c63 · span 1938706–1938716 |
| 92 | DaVita Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0000927066-26-000053 | CEO total compensation as printed in DaVita Inc.'s own proxy. As printed: 18,210,597. Filing ↗machine: r2 · c45 · span 800715–800725 |
| 93 | Becton, Dickinson and Company, Section 10b CEO total | DEF 14A | 2025-12-18 | 0001628280-25-057846 | CEO total compensation as printed in Becton, Dickinson and Company's own proxy. As printed: 17,129,140. Filing ↗machine: r2 · c27 · span 1173285–1173295 |
| 94 | Quest Diagnostics Incorporated, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013356 | CEO total compensation as printed in Quest Diagnostics Incorporated's own proxy. As printed: 15,498,479. Filing ↗machine: r2 · c17 · span 699327–699337 |
| 95 | ResMed Inc., Section 10b CEO total | DEF 14A | 2025-10-02 | 0000943819-25-000079 | CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 14,674,543. Filing ↗machine: span 1328668–1328678 |
| 96 | IDEXX Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0000874716-26-000064 | CEO total compensation as printed in IDEXX Laboratories, Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018 |
| 97 | Waters Corporation, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149657 | CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. Filing ↗machine: r5 · c18 · span 568522–568533 |
| 98 | Revvity, Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001193125-26-107266 | CEO total compensation as printed in Revvity, Inc.'s own proxy. As printed: 13,809,549. Filing ↗machine: span 751285–751295 |
| 99 | Henry Schein, Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001193125-26-146317 | CEO total compensation as printed in Henry Schein, Inc.'s own proxy. As printed: 12,013,915. Filing ↗machine: t221 · r3 · c35 · span 671366–671376 |
| 100 | Bio-Techne Corporation, Section 10b CEO total | DEF 14A | 2025-09-19 | 0001308179-25-000599 | CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. Filing ↗machine: span 792074–792083 |
| 101 | DexCom, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0001093557-26-000061 | CEO total compensation as printed in DexCom, Inc.'s own proxy. As printed: 7,985,960. Filing ↗machine: span 940364–940373 |
| 102 | Teleflex Incorporated, Section 10b CEO total | DEF 14A | 2026-04-13 | 0000096943-26-000039 | CEO total compensation as printed in Teleflex Incorporated's own proxy. As printed: 6,732,419. Filing ↗machine: span 558736–558745 |
| 103 | Walgreens Boots Alliance, Inc., Section 10b CEO total | DEF 14A | 2024-12-13 | 0001558370-24-016214 | CEO total compensation as printed in Walgreens Boots Alliance, Inc.'s own proxy. As printed: 2,500,000. Filing ↗machine: t333 · r24 · c18 · span 2342384–2342393 |
| 104 | Section 10a, AbbVie Inc. reciprocity | DEF 14A | — | 0001104659-26-033387 | AbbVie Inc.'s most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 105 | Section 10a, UnitedHealth Group Incorporated reciprocity | DEF 14A | — | 0001104659-26-046125 | UnitedHealth Group Incorporated names CVS Health in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 106 | Section 10a, Walmart Inc. reciprocity | DEF 14A | — | 0001193125-26-173673 | Walmart Inc. names CVS Health in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 107 | Section 10a, Danaher Corporation reciprocity | DEF 14A | — | 0000313616-26-000101 | Danaher Corporation's most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 108 | Section 10a, Humana Inc. reciprocity | DEF 14A | — | 0001104659-26-024799 | Humana Inc. names CVS Health in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 109 | Section 10a, Moderna, Inc. reciprocity | DEF 14A | — | 0001308179-26-000081 | Moderna, Inc.'s most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 110 | Section 10a, Henry Schein, Inc. reciprocity | DEF 14A | — | 0001193125-26-146317 | Henry Schein, Inc.'s most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 111 | Section 10a, Insulet Corp. reciprocity | DEF 14A | — | 0001140361-26-013333 | Insulet Corp.'s most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 112 | Section 10a, Baxter International Inc. reciprocity | DEF 14A | — | 0001628280-26-020330 | Baxter International Inc.'s most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 113 | Section 10a, IDEXX Laboratories, Inc. reciprocity | DEF 14A | — | 0000874716-26-000064 | IDEXX Laboratories, Inc.'s most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 114 | Section 10a, Elevance Health, Inc. reciprocity | DEF 14A | — | 0001156039-26-000031 | Elevance Health, Inc. names CVS Health in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 115 | Section 10a, Quest Diagnostics Incorporated reciprocity | DEF 14A | — | 0001140361-26-013356 | Quest Diagnostics Incorporated's most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 116 | Section 10a, DaVita Inc. reciprocity | DEF 14A | — | 0000927066-26-000053 | DaVita Inc.'s most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 117 | Section 10a, Boston Scientific Corporation reciprocity | DEF 14A | — | 0000885725-26-000025 | Boston Scientific Corporation's most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 118 | Section 10a, Centene Corporation reciprocity | DEF 14A | — | 0001071739-26-000077 | Centene Corporation names CVS Health in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 119 | Section 10a, Becton, Dickinson and Company reciprocity | DEF 14A | — | 0001628280-25-057846 | Becton, Dickinson and Company's most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 120 | Section 10a, Eli Lilly and Company reciprocity | DEF 14A | — | 0000059478-26-000029 | Eli Lilly and Company's most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 121 | Section 10a, The Cigna Group reciprocity | DEF 14A | — | 0001739940-26-000023 | The Cigna Group names CVS Health in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 122 | Section 10a, HCA Healthcare, Inc. reciprocity | DEF 14A | — | 0001193125-26-106142 | HCA Healthcare, Inc. names CVS Health in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 123 | Section 10a, Target Corporation reciprocity | DEF 14A | — | 0001628280-26-027508 | Target Corporation names CVS Health in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 124 | Section 10a, ResMed Inc. reciprocity | DEF 14A | — | 0000943819-25-000079 | ResMed Inc.'s most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 125 | Section 10a, Revvity, Inc. reciprocity | DEF 14A | — | 0001193125-26-107266 | Revvity, Inc.'s most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 126 | Section 10a, Stryker Corporation reciprocity | DEF 14A | — | 0000310764-26-000013 | Stryker Corporation's most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 127 | Section 10a, Teleflex Incorporated reciprocity | DEF 14A | — | 0000096943-26-000039 | Teleflex Incorporated's most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 128 | Section 10a, Waters Corporation reciprocity | DEF 14A | — | 0001193125-26-149657 | Waters Corporation's most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 129 | Section 10a, Bio-Techne Corporation reciprocity | DEF 14A | — | 0001308179-25-000599 | Bio-Techne Corporation's most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |
| 130 | Section 10a, DexCom, Inc. reciprocity | DEF 14A | — | 0001093557-26-000061 | DexCom, Inc.'s most recent proxy was read; its disclosed peer group does not include CVS Health. Filing ↗ |